Apomorphine Effects on Pain in Parkinson's Disease

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

July 31, 2023

Conditions
Parkinson Disease
Interventions
DRUG

Apomorphine Injectable Solution

"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"

DRUG

Placebo

"0.9% saline placebo injection~Other Names:~• Saline"

Trial Locations (1)

T2N4N1

RECRUITING

Movement Disorder Program, Foothills Medical Center, Alberta Health Services, Calgary

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Paladin Labs Inc.

OTHER

lead

University of Calgary

OTHER